Fresenius stock slips as stronger outlook meets market pressure

Fresenius raised its 2026 earnings outlook after a stronger third quarter, but the stock remained under pressure on Wednesday, November 11. The company reported the results on November 4 in an EQS company announcement carried by Financial Times.

Fresenius stock traded at 52.86 euros on Lang & Schwarz at 17:51 CET on Wednesday, November 11, 0.08 percent above the Xetra close of Wednesday, November 11. That Xetra close was 1.22 percent below Tuesday's close of 53.47 euros.

Third-quarter execution supports guidance

Group revenue reached 5,803 million euros in the third quarter, with organic growth of 5 percent. EBIT before special items rose to 638 million euros, while the margin expanded by 50 basis points to 11.0 percent.

Core EPS increased 14 percent at constant currency to 0.72 euros. Fresenius Kabi generated 391 million euros of EBIT, supported by its Growth Vectors and a 29 percent organic increase in biopharma revenue. Helios contributed 293 million euros of EBIT as revenue grew organically by 5 percent.

Management now expects constant-currency Core EPS growth in the upper half of the previous 10 percent to 15 percent range. The group EBIT margin indication was raised to above 11.5 percent, while the organic revenue-growth target remains 4 percent to 7 percent. The company also expects full-year interest expense below 300 million euros.

Pipeline investment adds a longer-term angle

Fresenius is scaling its biopharma business through an exclusive development agreement with WuXi Biologics. The agreement provides access to up to 37 potential biosimilar candidates and broadens the pipeline beyond the current portfolio.

The combination of margin expansion, lower interest expense and stronger performance at both operating divisions improves earnings visibility. Investors will nevertheless weigh the upgraded profit outlook against execution risks, healthcare regulation and the seasonal pattern in the hospital business.

The German healthcare group is also part of the broader DAX market environment.

More news and analyses on Fresenius stock.